Can you take tirzepatide or semaglutide after an eating disorder?
It isn't ruled out, but caution is advised. No label we checked lists a past eating disorder as a reason not to take tirzepatide (Mounjaro, Zepbound) or semaglutide (Ozempic, Wegovy), and none mentions eating disorders. A 2026 expert consensus advises screening first, caution after a past eating disorder, and generally avoiding them in active anorexia.
Do the medicine labels say anything about eating disorders?
None of the labels we searched lists eating disorders as a reason not to take tirzepatide or semaglutide, and none mentions them at all.12345678910
We searched the US, UK, EU, Australian and Canadian labels for the weight-loss brands. The US Zepbound label lists two contraindications (reasons not to use it). These are a personal or family history of a rare thyroid cancer (MTC or MEN 2), and a serious allergy to tirzepatide.1
An older weight-loss pill is different. The US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) says not to take naltrexone-bupropion (Contrave) with anorexia or bulimia nervosa. Its lists for Wegovy and Zepbound name only the thyroid cancer history.11
A silent label is not proof of safety. The main tirzepatide weight trial, SURMOUNT-1, excluded people with a severe psychiatric disorder in the past 2 years or any past suicide attempt. Its listed criteria do not mention eating disorders.12
What does research show for bingeing and restriction?
A 2026 review of 25 trials found these medicines cut binge eating slightly but raised dietary restraint, which its authors say may or may not be unhealthy.13
The review pooled 8,069 people, mostly with obesity. Only three trials actively recruited people with binge eating disorder or who saw themselves as binge eaters. Most trials were run or funded by drug makers. Twelve were at high risk of bias and none was at low risk.13
The EU Wegovy label says semaglutide lowers the frequency and intensity of cravings. In its STEP 5 trial, there was no clear effect on cravings for sweet food.6
Another 2026 review calls the evidence on bingeing limited and often inconsistent. It cites case reports of extreme appetite suppression and pathological food restriction, sometimes needing the medicine to stop.14 In a 2026 survey of 436 people with eating disorders, 32% had ever used a GLP-1 medicine. About 10% had misused one, such as taking more than prescribed.15
Binge eating disorder is not a listed use on the US Zepbound or Wegovy labels.12 In the US, lisdexamfetamine (Vyvanse) is approved for moderate to severe binge eating disorder in adults.16
What do prescribers check before starting?
A 2026 expert consensus and obesity guidance in the UK, Australia and Dubai all tell clinicians to screen for eating disorders before starting and to involve specialists where needed.24181920
A 2026 expert consensus in World Psychiatry says everyone should be screened for eating disorders before starting, and anyone who screens positive should be referred to an eating disorder specialist. It says to generally avoid these medicines in active anorexia nervosa, atypical anorexia, and bulimia with marked dietary restraint. After a past eating disorder, it advises caution, and it sees binge eating disorder as lower risk. It says this is not an absolute ban, and that monitoring should match the screening result.24
The NHS says to see a GP if you have, or think you may have, an eating disorder such as binge eating.17 NICE, which sets guidance for England, says diet plans should take account of eating disorders or disordered eating.18
Australia's 2024 obesity management algorithm says to ask about binge eating, purging or night eating. If symptoms suggest a problem, it advises referral to a dietitian or clinical psychologist with that expertise.19 Dubai's telehealth obesity guideline says almost 30% of patients with obesity have eating disorders, and tells clinicians to screen for them.20
Since February 2025, UK pharmacy regulator guidance says online prescribers must independently check a person's weight, height or BMI, according to a law firm's summary.23
Which side effects matter more if you restrict or purge?
Vomiting and diarrhoea on Zepbound can cause dehydration and kidney problems, its US Medication Guide says, and the NHS links frequent vomiting to bulimia's physical harms.121
The NHS links bulimia's physical problems to poor nutrition, making yourself sick a lot and overusing laxatives. Without the right support, it says bulimia can be life-threatening.21 Low blood sugar is more likely when Zepbound is used with insulin or a sulfonylurea, a type of diabetes medicine.1
What do people on GLP-1 medicines report about eating disorder history?
From public patient forums: 92 Reddit threads in r/Zepbound, r/mounjarouk, r/Mounjaro, r/Semaglutide, r/Ozempic and r/WegovyWeightLoss, read from October 2025 to October 2026. Personal reports, not medical evidence.
What people describe
- Matches the trials Many say food noise and binge or purge urges went quiet, including people with past bulimia, binge eating or anorexia. A 2026 review found binge eating fell slightly, though few trials enrolled people with a diagnosis.13
- Matches the research About half say restrictive thinking or undereating came back or got easier, including some whose history was only bingeing. The same review found restraint rose, and case reports describe pathological food restriction.1314
- Matches the research Several threads hold both kinds of story, with some people helped and others relapsing. A 2026 review calls the evidence limited and often inconsistent.14
- Not studied Several say vomiting from the medicine felt like purging or led back to it, and some describe laxative misuse. We found no study of this.
Advice people share
- Matches the guidelines Most suggest pairing the medicine with a therapist or dietitian experienced in eating disorders. Australia's obesity algorithm advises referral to a dietitian or clinical psychologist with that expertise.19
- Matches the NHS Many say to tell the prescriber everything, including skipped meals and purging. The NHS says to see a GP if you have, or think you may have, an eating disorder.17
- NICE says otherwise Several threads endorse very low intake, fasting or skipping meals, sometimes to people with an eating disorder history. NICE advises against nutritionally unbalanced restrictive diets and says to offer eating disorder assessment before low-calorie diets.18
In your country
No label we checked mentions eating disorders, so the answer is the same everywhere; what differs is the brands sold and which labels we could open.
Australia
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.
Label: The answer above applies.
Emergency number: 000
Canada
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.
Label: The answer above applies.
Emergency number: 911
France
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).
Label: The answer above applies.
Emergency number: 15 or 112
Germany
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.
Label: The answer above applies.
Emergency number: 112
India
Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).
Label: We did not open an Indian label for this page, so it relies on the US, UK and EU labels.
Emergency number: 112
Saudi Arabia
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.
Label: We did not open a Saudi label for this page, so it relies on the US, UK and EU labels.
Emergency number: 997 or 911
United Arab Emirates
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.
Label: We did not open a UAE label for this page, so it relies on the US, UK and EU labels.
Emergency number: 998 for an ambulance, or 999
United Kingdom
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.
Label: The answer above applies.
Emergency number: 999
United States
Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).
Label: The answer above applies.
Emergency number: 911
Contact your prescriber or a doctor right away if nausea, vomiting or diarrhoea does not go away.1 The NHS also advises seeing a GP if you think you might have bulimia, or if treatment for it is not helping.21
Read the full picture
Related questions
Sources
- US Zepbound (tirzepatide) prescribing information and Medication Guide, revised August 2026. Eli Lilly
- US Wegovy (semaglutide) prescribing information, revised June 2026. DailyMed
- UK Mounjaro KwikPen (tirzepatide) SmPC, last updated on emc 8 September 2026. emc
- UK Wegovy 2.4 mg FlexTouch (semaglutide) SmPC, last updated on emc 22 September 2026. emc
- EU Mounjaro (tirzepatide) product information. European Medicines Agency
- EU Wegovy (semaglutide) product information. European Medicines Agency
- Australian Mounjaro (tirzepatide) Product Information, October 2026. medsinfo
- Australian Wegovy (semaglutide) Product Information. medsinfo
- Canadian Zepbound (tirzepatide) Product Monograph. Health Canada
- Canadian Wegovy (semaglutide) Product Monograph. Health Canada
- NIDDK, US National Institutes of Health. Prescription medications to treat overweight and obesity. niddk.nih.gov
- SURMOUNT-1 (NCT04184622): a study of tirzepatide in participants with obesity or overweight. Eligibility criteria. ClinicalTrials.gov
- Emptage I, et al. The effectiveness of GLP-1 receptor agonists on binge eating in patients with obesity: a systematic review and meta-analysis. eClinicalMedicine. 2026;98:104007. PMC13523834
- Leziak A, Kochman K, Kocełak P. The dual role of GLP-1 receptor agonists in weight management and eating disorders: potential benefits and risks. J Psychiatr Res. 2026 (abstract). doi.org
- Healio. About 10% of patients with eating disorders have misused GLP-1 receptor agonists, 3 August 2026, reporting a JAMA Psychiatry research letter by Peiper NC, et al. (interim survey analysis). healio.com
- US Vyvanse (lisdexamfetamine) prescribing information. DailyMed
- NHS. Overweight and obesity in adults. nhs.uk
- NICE. Overweight and obesity management (NG246): physical activity and diet. nice.org.uk
- Markovic TP, Proietto J, Dixon JB, et al. The Australian Obesity Management Algorithm: a simple tool to guide the management of obesity in primary care, July 2024. diabetessociety.com.au
- Dubai Health Authority. Telehealth clinical guidelines for virtual management of obesity (CG-53), issued February 2024. dha.gov.ae
- NHS. Bulimia. nhs.uk
- MedlinePlus, US National Library of Medicine. Recognizing medical emergencies, giving the American College of Emergency Physicians' warning signs. medlineplus.gov
- CMS (law firm). Increased regulation of high-risk and weight loss medication: will new GPhC guidance strengthen safeguards?, 10 February 2025. cms.law
- Keshen A, Koning E, Allison KC, et al. Consensus-based clinical and research recommendations for use of glucagon-like peptide-1 receptor agonists in the context of eating disorders: a modified Delphi study. World Psychiatry. 2026;25(3):465-474. doi.org
Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked by Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write